Actively Recruiting
Implementation of the Methylome in the Characterization of Solid Tumors
Led by IRCCS Azienda Ospedaliero-Universitaria di Bologna · Updated on 2025-12-18
180
Participants Needed
1
Research Sites
136 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
This study aims to investigate the functional consequences of specific methylation changes and to examine the clinical implications of these alterations. Methylation analysis is a powerful tool for understanding the molecular mechanisms of brain tumors and other solid tumors and can help identify new diagnostic and therapeutic targets. By analyzing DNA methylation patterns in tumor tissue, it is possible to identify genes that are silenced or activated by methylation. This information can be used to develop new biomarkers for early diagnosis and to identify new therapeutic targets that can be used to reverse methylation-mediated gene silencing.
CONDITIONS
Official Title
Implementation of the Methylome in the Characterization of Solid Tumors
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Confirmed diagnosis of gliomas, malignant thyroid neoplasms, or endometrial carcinomas according to WHO Nomenclature
- Availability of adequate tumor tissue material for analysis, specifically at least 3 sections of 10 m of FFPE
You will not qualify if you...
- No exclusion criteria specified
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
IRCCS Azienda Ospedaliero Univesitaria di Bologna
Bologna, BO, Italy, 40138
Actively Recruiting
Research Team
G
Giovanni Tallini, Prof.
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
0
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here